var data={"title":"Oxandrolone: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Oxandrolone: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6693?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=oxandrolone-drug-information\" class=\"drug drug_general\">see &quot;Oxandrolone: Drug information&quot;</a> and <a href=\"topic.htm?path=oxandrolone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Oxandrolone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709184\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Peliosis hepatis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Peliosis hepatis, a condition in which liver and, sometimes, splenic tissue is replaced with blood-filled cysts, has occurred in patients receiving androgenic anabolic steroids. These cysts are sometimes present with minimal hepatic dysfunction and have been associated with liver failure. Often, they are not recognized until life-threatening liver failure or intra-abdominal hemorrhage develops. Withdrawal of drug usually results in complete disappearance of lesions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Liver cell tumors:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Most often these tumors are benign and androgen-dependent, but fatal malignant tumors have occurred. Withdrawal of drug often results in regression or cessation of tumor progression. However, hepatic tumors associated with androgens or anabolic steroids are much more vascular than other hepatic tumors and may be silent until life-threatening, intra-abdominal hemorrhage develops.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Blood lipid changes:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Blood lipid changes associated with increased risk of atherosclerosis are seen in patients treated with androgens and anabolic steroids. These changes include decreased high-density lipoprotein (HDL) and, sometimes, increased low-density lipoprotein (LDL). The changes may be very marked and could have a serious impact on the risk of atherosclerosis and coronary artery disease.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204321\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Oxandrin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1028862\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Anabolic Steroid</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Androgen</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1028882\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=oxandrolone-drug-information\" class=\"drug drug_general\">see &quot;Oxandrolone: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Burn management, severe; to increase lean muscle mass and promote wound healing:</b> Limited data available: Children and Adolescents: Oral: 0.1 mg/kg/dose twice daily for up to 12 months has been shown to increase lean body mass, bone mineral density, and muscle strength; shortened length of ICU stay and improved donor site wound healing were also observed (Hart 2001; Jeschke 2007; Murphy 2004; Porro 2012; Przkora 2005). Benefits have been shown to persist for up to 5 years post burn (Porro 2012; Przkora 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Constitutional delay of growth and puberty (CDGP) (males):</b> Limited data available: Children and Adolescents 9 to 16 years: Oral: 1.25 to 2.5 mg once daily in the evening; usual duration: 3 to 12 months although longer (~5 years) has been reported (Albanese 1994; Buyukgebiz 1990; Papadimitriou 1991; Schroor 1995; Stanhope 1985; Stanhope 1988; Tse 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Turner Syndrome (females):</b> Limited data available: Children and Adolescents &ge;8 years: Oral: Reported range: 0.03 to 0.06 mg/kg/day at bedtime in combination with growth hormone and/or estrogen; maximum single dose: 2.5 mg/dose; due to risks of dose-related virilization, doses &ge;0.05 mg/kg/day should generally be avoided. Typically, therapy initiated at 8 to 9 years of age and continued until goal height attained or further growth is unlikely (eg, bone age &ge;14 years and growth velocity &lt;2 cm/year) (Bareille 1997; NIH [Bondy 2007]; Freriks 2012; Gault 2011; Haeusler 1995; Menke 2010; Nilsson 1996).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Weight gain, adjunct:</b> Children and Adolescents: Oral: Total daily dose: &le;0.1 mg/kg; may be repeated intermittently as needed; in adult patients, the daily dose is divided 2 to 4 times daily; typical duration of therapy: 2 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Weight gain, adjunct:</b> Oral: 2.5 to 20 mg/day in 2 to 4 divided doses based on individual response; a course of therapy of 2 to 4 weeks is usually adequate. This may be repeated intermittently as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> All patients: There are no dosage adjustments provided in the manufacturer's labeling. Caution is recommended because of the propensity of oxandrolone to cause edema and water retention.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204313\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oxandrin: 2.5 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oxandrin: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg, 10 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204299\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204339\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-III</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16122838\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1028863\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who, without definite pathophysiologic reasons, fail to gain or to maintain normal weight; to offset protein catabolism with prolonged corticosteroid administration and for the relief of bone pain associated with osteoporosis (All indications: FDA approved in children and adults); has also been used in the management of Turner syndrome in girls, constitutional delay of growth and puberty (CDGP), and for postoperative burn management to increase lean muscle mass and promote wound healing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204343\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Deepening of the voice (females), depression, excitement, habituation, insomnia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris (females and prepubertal males), androgenetic alopecia (females)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Changes in libido, decreased glucose tolerance, decreased HDL cholesterol, electrolyte disturbance, gynecomastia, hirsutism (females), increased LDL cholesterol, inhibition of gonadotropin secretion, menstrual disease (females)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Clitoromegaly (females), epididymitis (postpubertal males), erectile dysfunction (prepubertal males; increased or persistent erections), impotence (postpubertal males), inhibition of testicular function (postpubertal males), irritable bladder (postpubertal males), oligospermia (postpubertal males), phallic enlargement (prepubertal males), priapism (chronic; postpubertal males), testicular atrophy (postpubertal males)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Clotting factors suppression, prolonged prothrombin time</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Cholestatic jaundice, hepatocellular neoplasm, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum bilirubin, peliosis hepatitis (long-term therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Increased creatine phosphokinase, premature epiphyseal closure (children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased creatinine clearance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Hepatic necrosis, hepatotoxicity (idiosyncratic; Chalasani 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204316\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Nephrosis; carcinoma of breast (women with hypercalcemia or men) or prostate; hypercalcemia; pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204303\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Blood lipid changes: <b>[U.S. Boxed Warning]: May cause blood lipid changes with increased risk of arteriosclerosis.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: <b>[U.S. Boxed Warning]: Anabolic steroids may cause peliosis hepatis or liver cell tumors which may not be apparent until liver failure or intra-abdominal hemorrhage develops.</b> Discontinue in case of cholestatic hepatitis with jaundice or abnormal liver function tests. Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Breast cancer: Use with caution in patients with breast cancer; may cause hypercalcemia by stimulating osteolysis. Discontinue use if hypercalcemia occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in patients with diabetes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; COPD: Use with caution in patients with COPD.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal impairment); may cause fluid retention.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Warfarin: Use caution with concomitant warfarin therapy; warfarin dose may need to be significantly decreased.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in elderly patients, they may be at greater risk for prostatic hyperplasia, prostate cancer, fluid retention, and transaminase elevations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: May accelerate bone maturation without producing compensatory gain in linear growth in children; effect may continue for 6 months after the drug is stopped; in prepubertal children perform radiographic examination of the left hand and wrist every 6 months to determine the rate of bone maturation and to assess the effect of treatment on the epiphyseal centers.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Females: May cause mild virilization in females; monitor for signs of virilization (deepening of the voice, hirsutism, acne, clitoromegaly). Discontinue with evidence of mild virilization in female patients; early discontinuation may prevent irreversible virilization.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Anabolic steroids have not been shown to improve athletic ability. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299799\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204307\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=94655&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Androgens may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Glucose Lowering Agents: Androgens may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">C1 inhibitors: Androgens may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the fluid-retaining effect of Androgens.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204308\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204318\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated in women who are or may become pregnant; masculinization of the fetus has been reported.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1028888\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests, lipid profile, hemoglobin/hematocrit; INR/PT in patients on anticoagulant therapy </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Children: Radiographs of left wrist every 6 months to assess bone maturation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Females: Signs of virilization (deepening voice, hirsutism, acne, clitoromegaly); urine and serum calcium in women with breast cancer </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204302\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Synthetic testosterone derivative with similar androgenic and anabolic actions</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F854656\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed (Orr  2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Protein binding: 95% (Orr 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 10-13 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak serum concentration: ~1 hour (Orr 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (28% as unchanged drug) (Orr 2004)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12737086\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">A 1 mg/mL oral suspension may be made with tablets and either a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;, or a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg;.  Crush twenty-four 2.5 mg tablets in a mortar to a fine powder. Add small portions of chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost </b>60 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Thoroughly mix the suspension by shaking. Label &ldquo;shake well&rdquo; and &ldquo;protect from light&rdquo;. Stable for 90 days at room temperature (Johnson, 2011).</p>\n    <div class=\"reference\">Johnson CE, Cober MP, Hawkins KA, et al, &ldquo;Stability of Extemporaneously Prepared Oxandrolone Oral Suspensions,&rdquo; <i>Am J Health-Syst Pharm</i>, 2011, 68(6):519-21.<span class=\"pubmed-id\">21378300</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204317\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Oxandrin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (100): $785.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (60): $1,597.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Oxandrolone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (100): $552.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (60): $1,125.03</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539909\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Kicker (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Albanese A, Kewley GD, Long A, Pearl KN, Robins DG, Stanhope R. Oral treatment for constitutional delay of growth and puberty in boys: a randomized trial of an anabolic steroid or testosterone undecanoate. <i>Arch Dis Child</i>. 1994;71(4):315-317.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxandrolone-pediatric-drug-information/abstract-text/7979523/pubmed\" target=\"_blank\" id=\"7979523\">7979523</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bareille P, Massarano AA, Stanhope R. Final height outcome in girls with Turner syndrome treated with a combination of low dose oestrogen and oxandrolone. <i>Eur J Pediatr</i>. 1997;156:358-362.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxandrolone-pediatric-drug-information/abstract-text/9177976/pubmed\" target=\"_blank\" id=\"9177976\">9177976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bondy CA, Turner Syndrome Consensus Study Group. Care of girls and women with Turner Syndrome: a guideline of the Turner Syndrome Study Group.<i> J Clin Endocrinol Metab</i>. 2007;92(1):10-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxandrolone-pediatric-drug-information/abstract-text/17047017/pubmed\" target=\"_blank\" id=\"17047017\">17047017</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buyukgebiz A, Hindmarsh PC, Brook CGD. Treatment of constitutional delay of growth and puberty with oxandrolone compared with growth hormone. <i>Arch Dis Child</i>. 1990;65(4):448-449.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxandrolone-pediatric-drug-information/abstract-text/2346341/pubmed\" target=\"_blank\" id=\"2346341\">2346341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxandrolone-pediatric-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freriks K, Sas TCJ, Traas MAF, et al. Long-term effects of previous oxandrolone treatment in adult women with Turner syndrome. <i>Eur J Endocrinol</i>. 2012;168(1):91-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxandrolone-pediatric-drug-information/abstract-text/23076845/pubmed\" target=\"_blank\" id=\"23076845\">23076845</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gault EJ, Perry R, Cole TJ, et al. Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: randomized, double blind, placebo controlled trial. <i>BMJ</i>. 2011;342:d1980.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxandrolone-pediatric-drug-information/abstract-text/21493672/pubmed\" target=\"_blank\" id=\"21493672\">21493672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hart DW, Wolf SE, Ramzy PI, et al. Anabolic effects of oxandrolone after severe burn. <i>Ann Surg</i>. 2001;233(4):556-564.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxandrolone-pediatric-drug-information/abstract-text/11303139/pubmed\" target=\"_blank\" id=\"11303139\">11303139</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haeusler G, Frisch H, Schmitt K, et.al. Treatment of patients with Ullrich-Turner syndrome with conventional doses of growth hormone and the combination with testosterone or oxandrolone: effect on growth, IGF-I and IGFBP-3 concentrations. <i>Eur J Pediatr</i>. 1995;154(6):437-444.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxandrolone-pediatric-drug-information/abstract-text/7545577/pubmed\" target=\"_blank\" id=\"7545577\">7545577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeschke MG, Finnerty CC, Suman OE, Kulp G, Mlcak RP, Herndon DN. The effect of oxandrolone on the endocrinologic, inflammatory, and hypermetabolic responses during the acute phase postburn. <i>Ann Surg</i>. 2007;246(3):351-360.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxandrolone-pediatric-drug-information/abstract-text/17717439/pubmed\" target=\"_blank\" id=\"17717439\">17717439</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menke LA, Sas TCJ, de Muinck Keizer-Schrama SMPF, et al. Efficacy and safety of oxandrolone in growth hormone-treated girls with Turner Syndrome. <i>J Clin Endocrinol Metab</i>. 2010;95(3):1151-1160.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxandrolone-pediatric-drug-information/abstract-text/20061421/pubmed\" target=\"_blank\" id=\"20061421\">20061421</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy KD, Thomas S, Mlcak RP, Chinkes DL, Klein GL, Herndon DN. Effects of long-term oxandrolone administration in severely burned children. <i> Surgery</i>. 2004;136(2):219-224.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxandrolone-pediatric-drug-information/abstract-text/15300183/pubmed\" target=\"_blank\" id=\"15300183\">15300183</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nilsson KA, Albertsson-Wikland K, Alm J, et al. Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone. <i>J Clin Endocrinol Metab</i>. 1996;81(2):635-640.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxandrolone-pediatric-drug-information/abstract-text/8636281/pubmed\" target=\"_blank\" id=\"8636281\">8636281</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders. Review of efficacy and safety. <i>Drugs</i>. 2004;64(7):725-750.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxandrolone-pediatric-drug-information/abstract-text/15025546/pubmed\" target=\"_blank\" id=\"15025546\">15025546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Papadimitriou A, Wacharasindhu S, Pearl K, Preece MA, Stanhope R. Treatment of constitutional growth delay in prepubertal boys with a prolonged course of low dose oxandrolone. <i>Arch Dis Child</i>. 1991;66(7):841-843.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxandrolone-pediatric-drug-information/abstract-text/1863096/pubmed\" target=\"_blank\" id=\"1863096\">1863096</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Porro LJ, Herndon DN, Rodriguez NA, et al. Five-year outcomes after oxandrolone administration in severely burned children: a randomized clinical trial of safety and efficacy. <i>J Am Coll Surg</i>. 2012;214(4):489-504.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxandrolone-pediatric-drug-information/abstract-text/22463890/pubmed\" target=\"_blank\" id=\"22463890\">22463890</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Przkora R, Jeschke MG, Barrow RE, et al. Metabolic and hormonal changes of severely burned children receiving long-term oxandrolone treatment. <i>Ann Surg</i>. 2005;242(3):384-389.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schroor EJ, van Weissenbruch MM, Knibbe P, Delemarre-van de Waal HA. The effect of prolonged administration of an anabolic steroid (oxandrolone) on growth in boys with constitutionally delayed growth and puberty.<i> Eur J Pediatr</i>. 1995;154(12):953-957.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxandrolone-pediatric-drug-information/abstract-text/8801102/pubmed\" target=\"_blank\" id=\"8801102\">8801102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stanhope R, Brook CGD. Oxandrolone in low dose for constitutional delay of growth and puberty in boys. <i>Arch Dis Child</i>. 1985;60(4):379-381.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxandrolone-pediatric-drug-information/abstract-text/4004317/pubmed\" target=\"_blank\" id=\"4004317\">4004317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stanhope R, Buchanan CR, Fenn GC, Preece MA. Double blind placebo controlled trial of low dose oxandrolone in the treatment of boys with constitutional delay of growth and puberty. <i>Arch Dis Child</i>. 1988;63(5):501-505.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxandrolone-pediatric-drug-information/abstract-text/3389864/pubmed\" target=\"_blank\" id=\"3389864\">3389864</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tse WY, Buyukgebiz A, Hindmarsh PC, Stanhope R, Preece MA, Brook CG. Long-term outcome of oxandrolone treatment in boys with constitutional delay of growth and puberty. <i>J Pediatr</i>. 1990;117(4):588-591.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxandrolone-pediatric-drug-information/abstract-text/2213384/pubmed\" target=\"_blank\" id=\"2213384\">2213384</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 94655 Version 37.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709184\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F204321\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1028862\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1028882\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F204313\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F204299\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F204339\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F16122838\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1028863\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F204343\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F204316\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F204303\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299799\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F204307\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F204308\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F204318\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1028888\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F204302\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F854656\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F12737086\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F204317\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539909\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/94655|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=oxandrolone-drug-information\" class=\"drug drug_general\">Oxandrolone: Drug information</a></li><li><a href=\"topic.htm?path=oxandrolone-patient-drug-information\" class=\"drug drug_patient\">Oxandrolone: Patient drug information</a></li></ul></div></div>","javascript":null}